 Fusion Pharmaceuticals Inc NASDAQ: FUSN has entered into a clinical trial collaboration with Merck Co NYSE: MRK to evaluate Fusions lead candidate, FPI-1434, in combination with Mercks Keytruda in patients with solid tumors expressing insulin-like growth factor 1 receptor IGF-1R. The planned Phase 12 combination trial will evaluate the safety, tolerability, and pharmacokinetics of FPI-1434 in combination with pembrolizumab. 